Literature DB >> 21959031

A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.

Mark J Boschen1.   

Abstract

OBJECTIVE: Generalized anxiety disorder (GAD) is a chronic anxiety disorder that leads to significant functional impairment and reduced quality of life. Pregabalin is a novel analogue of the inhibitory neurotransmitter gamma amino butyric acid, which has been proposed as a treatment for a range of conditions including GAD. This study examined the efficacy of pregabalin for GAD across published trials, using a meta-analytic method.
METHOD: This study examined the 7 published placebo-controlled trials of GAD using pregabalin, and, using meta-analytic techniques, we calculated the effect size of treatment with pregabalin (compared with placebo) on a total of 1352 people.
RESULTS: The overall effect size of pregabalin in the treatment of GAD was Hedges' g = 0.364, with an effect size of 0.349 on psychic anxiety symptoms and of 0.239 on somatic anxiety symptoms.
CONCLUSION: Pregabalin is an efficacious therapy for GAD, although effect sizes are smaller than those from earlier studies. Limitations and future research directions are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959031     DOI: 10.1177/070674371105600907

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  8 in total

Review 1.  Pregabalin: a review of its use in adults with generalized anxiety disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

Review 2.  Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review.

Authors:  Jeffrey R Strawn; Laura Geracioti; Neil Rajdev; Kelly Clemenza; Amir Levine
Journal:  Expert Opin Pharmacother       Date:  2018-07       Impact factor: 3.889

3.  Involvement of the dopaminergic system in the reward-related behavior of pregabalin.

Authors:  Yusuf S Althobaiti; Farooq M Almutairi; Fahad S Alshehri; Ebtehal Altowairqi; Aliyah M Marghalani; Amal A Alghorabi; Walaa F Alsanie; Ahmed Gaber; Hashem O Alsaab; Atiah H Almalki; Alqassem Y Hakami; Turki Alkhalifa; Ahmad D Almalki; Ana M G Hardy; Zahoor A Shah
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

Review 4.  Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients.

Authors:  Chuan Zou; Xiang Ding; Joseph H Flaherty; Birong Dong
Journal:  Neuropsychiatr Dis Treat       Date:  2013-11-01       Impact factor: 2.570

5.  Psychometric properties of the Generalized Anxiety Disorder Questionnaire - IV (GAD-Q-IV) in postpartum mothers.

Authors:  Mark E Pierson; Jason M Prenoveau; Michelle G Craske; Elena Netsi; Alan Stein
Journal:  Psychol Assess       Date:  2017-02-20

6.  Pregabalin: Potential for Addiction and a Possible Glutamatergic Mechanism.

Authors:  Yusuf S Althobaiti; Atiah Almalki; Hashem Alsaab; Walaa Alsanie; Ahmed Gaber; Qasim Alhadidi; Ana Maria Gregio Hardy; Abdulrahman Nasr; Omar Alzahrani; Creed M Stary; Zahoor A Shah
Journal:  Sci Rep       Date:  2019-10-22       Impact factor: 4.379

7.  Effectiveness of pregabalin as monotherapy or combination therapy for neuropathic pain in patients unresponsive to previous treatments in a Spanish primary care setting.

Authors:  Emilio Blanco Tarrio; Rafael Gálvez Mateos; Enric Zamorano Bayarri; Vanessa López Gómez; Maria Pérez Páramo
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

8.  Potential Benefits of N-Acetylcysteine in Preventing Pregabalin-Induced Seeking-Like Behavior.

Authors:  Atiah H Almalki; Hashem O Alsaab; Walaa F Alsanie; Ahmed Gaber; Turki Alkhalifa; Ahmad Almalki; Omar Alzahrani; Ana Maria Gregio Hardy; Qasim Alhadidi; Zahoor A Shah; Yusuf S Althobaiti
Journal:  Healthcare (Basel)       Date:  2021-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.